Regor Therapeutics

Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist RGT-075 for the Treatment of Obesity
Drugs.com
Sun, 03/10/24 - 08:28 pm
Regor Therapeutics
clinical trials
GLP-1 agonist
RGT-075
obesity
Pfizer ordered to disclose FBI communications in trade secrets case
Endpoints
Tue, 02/7/23 - 06:39 pm
Pfizer
trade secrets
FBA
Regor Therapeutics
Eli Lilly pens $1.5B biobucks pact with China's Regor for metabolic disease work
Fierce Biotech
Fri, 12/10/21 - 11:05 am
Eli Lilly
China
Regor Therapeutics
metabolic disorders